UT
UCL Technology Fund
Venture CapitalActiveUCL TF is dedicated to investing in intellectual property commercialisation opportunities arising from UCLвАЩs world-class research base
16
Investments
3
Exits
$250M
AUM
18.8%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for UCL Technology Fund.
Investment Thesis & Strategy
UCL Technology Fund invests in various stages of fintech and venture capital companies that originate from UCL's research base and focus on intellectual property commercialization.
Investment Activity
Deals per year over the last 7 years
1
20163
20170
20180
20192
20203
20212
2022Portfolio Companies
Selected investments from their portfolio of 16 companies
V
Vivan Therapeutics
Biotech · Series A, 2022
P
Purespring Therapeutics
Biotech · Series A, 2022
S
Sana Health
Healthcare · Series A, 2021
i
iLoF
Biotech · Series A, 2021
O
Ochre Bio
Biotech · Series A, 2021
R
Resolution Therapeutics
Biotech · Series A, 2020
B
Baseimmune
Biotech · Seed, 2020
T
Tropic Biosciences
Biotech · Series A, 2017
U
Ultromics
Healthcare · Series A, 2017
E
Exonate
Biotech · Series A, 2017
I
Inivata
Biotech · Series A, 2016
Notable Exits
CompanyTypeYearValue / Acquirer
Mission TherapeuticsAcquisition2024—
Autifony TherapeuticsAcquisition2021—
Hutchison China MediTechIPO2016—
Frequently Asked Questions
UCL Technology Fund focuses on Series A, Series B, Series C+ stage investments.